CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Your pituitary does not release growth hormone in a steady stream. It fires in pulses, sharp bursts that spike high and then drop back down, and those spikes are what actually drive the downstream effects you are chasing: IGF-1 production, fat metabolism, tissue repair. The flat baseline in between those pulses is almost as important as the peaks, because your receptors need time without stimulation to reset and respond fully to the next burst.

That pulse-and-reset rhythm is the whole architecture the system is built on, and everything about how secretagogues work makes sense once you understand it.

Here is the basic chain. Your hypothalamus releases something called GHRH, which stands for growth hormone releasing hormone, and this is the signal that tells your pituitary to fire a pulse of growth hormone. A separate signal called ghrelin, released primarily from the stomach, hits a different receptor on the pituitary and amplifies that same pulse. Those two signals working together produce a much bigger GH spike than either one alone. After the pulse fires, your body releases something called somatostatin, which is essentially the brake, and it suppresses further GH release until the next cycle begins. CJC-1295 without DAC mimics GHRH, and Ipamorelin mimics ghrelin, so the combination pushes on both accelerators at the same time and produces a larger pulse while leaving the brake system fully intact.

That is the map. Now the four decisions sit inside that map, and each one makes more sense with it.

The DAC question is really a question about whether you want pulses or a flat line. DAC stands for drug affinity complex, and it is a chemical modification that lets CJC-1295 bind to albumin in your blood, extending the half-life from roughly thirty minutes up to around seven days. That sounds like an upgrade because less frequent injections are more convenient, but it fundamentally changes what you are doing. Instead of giving your pituitary a sharp GHRH signal that triggers a pulse and then clears, you are giving it a constant low-level stimulus around the clock. The pituitary responds to amplitude and timing, not just presence, and a constant GHRH signal produces a blunted, flattened output rather than the sharp spikes the whole downstream system is calibrated for. If your goal is a flat, sustained elevation in growth hormone, exogenous recombinant GH already does that and comes with decades of clinical trial data behind it. CJC-1295 without DAC is the version that actually preserves the architecture you are trying to optimize.

The blend question comes down to math, and the math matters because dosing errors compound quickly with peptides. When you buy a pre-mixed vial of CJC and Ipamorelin together, the two compounds share the same reconstituted volume, so you have to track both at once. A common configuration is five milligrams of each compound in two milliliters of bacteriostatic water, which gives you a concentration of 2.5 milligrams per milliliter for each peptide. On a standard insulin syringe where ten units equals 0.1 milliliter, that ten-unit draw gives you 250 micrograms of CJC and 250 micrograms of Ipamorelin simultaneously. Keeping that math written down matters because if you dilute differently or pull a different volume, the dose ratio shifts without you realizing it.

The cycling question is where most people have the mechanism exactly backwards, and the video script named this directly so it is worth going deeper. The common belief is that you cycle secretagogue protocols because the body adapts to continuous peptide use as a general rule, and that is partially right but points at the wrong receptor. CJC-1295 works through GHRH receptors, and those receptors do not meaningfully desensitize under continuous stimulation. The evidence for this comes from tesamorelin, which is a GHRH analogue used clinically for HIV-associated lipodystrophy, and in the FDA approval trials it was run continuously for 52 weeks. IGF-1 levels that were established at week 26 held steady all the way through week 52 without meaningful decline. The GHRH side of this protocol is not the problem.

Ipamorelin works through something called the ghrelin receptor, technically designated GHSR1a, and this receptor behaves very differently under continuous stimulation. The mechanism behind desensitization here involves something called beta-arrestin recruitment, which is a process where the receptor essentially gets flagged for internalization after repeated activation, meaning the cell physically reduces the number of available receptors on its surface. Less receptor availability means less signal per dose, so the same injection produces a progressively smaller response. In practical terms, continuous use without a break leads to IGF-1 levels dropping somewhere between 20 and 30 percent from the peak achieved earlier in the protocol, even with identical dosing, and this typically becomes measurable around the 12 to 16 week mark. The three months on, one month off structure gives the ghrelin receptors time to restore their surface density before the next cycle begins.

The fourth decision, when to move to exogenous growth hormone, is where the feedback loop architecture becomes the central issue. Secretagogues work within your natural production ceiling. Whatever your pituitary is capable of producing, they help you get closer to that maximum output while keeping the feedback system intact, meaning somatostatin still functions as the brake, your own production patterns are preserved, and the system remains responsive. Exogenous growth hormone bypasses that ceiling entirely and adds GH that is completely outside your body's regulatory loop.

The problem is that you cannot run both at the same time and expect the secretagogues to do anything useful. When exogenous GH enters the bloodstream, it triggers a somatostatin response, and that somatostatin suppresses the GHRH pathway by approximately 86 percent. That means the CJC-1295 you are injecting is hitting a receptor system that is almost entirely shut down by the very thing you are trying to stack it with. The two approaches are not additive. They are antagonistic in practice, and running both simultaneously means you are spending money on a peptide that cannot function.

The underlying principle across all four decisions is the same: the pulsatile architecture your pituitary uses is not a quirk to work around. It is the mechanism that makes the whole system work, and every choice in building one of these protocols either protects that architecture or erodes it.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness